Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2001081417) USE OF TACI AS AN ANTI-TUMOR AGENT
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2001/081417 International Application No.: PCT/US2001/040626
Publication Date: 01.11.2001 International Filing Date: 27.04.2001
Chapter 2 Demand Filed: 19.11.2001
IPC:
A61K 38/00 (2006.01) ,C07K 14/705 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
14
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435
from animals; from humans
705
Receptors; Cell surface antigens; Cell surface determinants
Applicants:
AMBROSE, Christine [US/US]; US (UsOnly)
THOMPSON, Jeffrey [US/US]; US (UsOnly)
SCHNEIDER, Pascal [CH/CH]; CH (UsOnly)
RENNERT, Paul [US/US]; US (UsOnly)
BIOGEN, INC. [US/US]; 14 Cambridge Centre Cambridge, MA 02142, US (AllExceptUS)
APOXIS SA [CH/CH]; 22, chemin des Croisettes CH-1066 Epalinges, CH (AllExceptUS)
Inventors:
AMBROSE, Christine; US
THOMPSON, Jeffrey; US
SCHNEIDER, Pascal; CH
RENNERT, Paul; US
Agent:
MILLER, Suzanne, E. ; Woodcock Washburn LLP 46th floor One Liberty Place Philadelphia, PA 19103, US
Priority Data:
60/199,94627.04.2000US
Title (EN) USE OF TACI AS AN ANTI-TUMOR AGENT
(FR) TACI UTILISEE EN TANT QU'AGENT ANTITUMORAL
Abstract:
(EN) A method of treating a mammal for a condition associated with undesired cell proliferation comprising administering to said mammal an effective amount an effective amount of a TACI reagent, wherein said reagent extends mean survival time of said mammal by about 10 % or more as compared to the absence of administering the TACI reagent.
(FR) Méthode de traitement d'un mammifère pour un état associé à la prolifération cellulaire indésirable, qui consiste à administrer audit mammifère une dose efficace d'un réactif TACI, lequel prolonge la durée de vie moyenne dudit mammifère d'environ 10 % ou plus par rapport au cas dans lequel ledit réactif TACI n'est pas administré.
front page image
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
African Regional Intellectual Property Organization (ARIPO) (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (EPO) (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)